Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and...

Full description

Bibliographic Details
Published in:Journal of Market Access & Health Policy
Main Authors: Goran Medic, Daria Korchagina, Katherine Eve Young, Mondher Toumi, Maarten Jacobus Postma, Micheline Wille, Michiel Hemels
Format: Article
Language:English
Published: MDPI AG 2017-01-01
Subjects:
Rare diseases
orphan drugs
pricing
treatment cost
Europe
Online Access:http://dx.doi.org/10.1080/20016689.2017.1299665

Internet

http://dx.doi.org/10.1080/20016689.2017.1299665

Similar Items